Inscripta raises additional $20 million in Series C financing round
Category: #health  By Nikita Chaurasia  Date: 2019-04-06
  • share
  • Twitter
  • Facebook
  • LinkedIn

Inscripta raises additional $20 million in Series C financing round

Inscripta is working to develop a full suite of gene-editing tools (reagents, software and instruments) to increase the efficiency and speed of CRISPR-based gene-editing

The US-based gene-editing technology company Inscripta has announced that it has raised additional $20 million in its previously declared Series C financing. The new funding, which comes from existing investors, adds to the $85.5 million financing that the company announced in 2018. The total amount raised now stands at $105.5 million.

According to the press release by Inscripta, the existing investors are Foresite, MLS Capital, Venrock, NanoDimension, Paladin Capital Group and Mérieux Développement. Inscripta is working to develop a full suite of gene-editing tools (reagents, software and instruments) to increase the efficiency and speed of CRISPR-based gene-editing.

The tools being developed by Inscripta include CRISPR enzyme family, called MADzymes; custom nucleases for commercial partners and researchers; and a full suite of gene-editing tools (reagents, software and instruments).

John Stuelpnagel, Chairman, Board of Directors, Inscripta, has reportedly said that researchers need a scale transformation to make gene editing efforts more useful and informative.

Reportedly, Inscripta had announced the broad adoption of MAD7 in December 2018. MAD7 is a proprietary CRISPR enzyme which has been offered to academic and commercial researchers without any upfront licensing fees or “reach-through royalties” on discoveries made using the technology.

For the record, MADzymes have different cut efficiencies, different PAM recognition sequences, different enzyme kinetics and reduced sizes. The first enzyme MAD7’s gene editing systems were patented recently. The enzyme is reportedly effective in microbial as well as mammalian systems. The robust editing activities have been shown by MAD7 in prokaryotic as well as eukaryotic microbes.

For the uninitiated, Colorado-based Inscripta is a gene-editing technology company which creates tools to revolutionize human life. The company works to provide control to researchers for cutting edge, single cell engineering.

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Nikita Chaurasia    

Nikita Chaurasia

Having always been daft at wordplay, Nikita Chaurasia, post the completion of post-graduation, commenced her journey into the content generation cosmos. Endowed with a professional MBA degree in Advertising and Public Relations, Nikita strives to integrate her creativ...

Read More

More News By Nikita Chaurasia

Tmunity doses first patient in Phase 1 CART-TnMUC1 clinical trial
Tmunity doses first patient in Phase 1 CART-TnMUC1 clinical trial
By Nikita Chaurasia

Tmunity Therapeutics Inc., a clinical-stage biotherapeutics firm focused on advanced T-cell immunotherapy, has reportedly dosed the first patient in its Phase 1 CART-TnMUC1-01 clinical trial with TnMUC1 (Tn/STn glycoform of mucin 1) CAR-T (chimeric a...

Hyundai and Uber team up to develop all-electric flying taxis
Hyundai and Uber team up to develop all-electric flying taxis
By Nikita Chaurasia

In the midst of technological advancements increasing at a commendable pace, Uber’s flying taxi initiative seems to be edging closer to reality – the reality of establishing flying cars in the near future. The ride-hailing giant has appar...

BioXcel begins Phase 3 BXCL501 trial for treating SCZ & bipolar disorder
BioXcel begins Phase 3 BXCL501 trial for treating SCZ & bipolar disorder
By Nikita Chaurasia

BioXcel Therapeutics, Inc., a clinical-stage biopharmaceutical firm leveraging artificial intelligence approaches to advance the next wave of medicines in immuno-oncology and neuroscience, has reportedly announced the initiation of its SERENITY progr...